Investigating immune responses in non-muscle-invasive bladder cancer
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
This study is looking at how your immune system reacts to the BCG treatment for non-muscle-invasive bladder cancer, with the hope of finding ways to make the treatment work better and reduce the chances of the cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11020945 on NIH RePORTER |
What this research studies
This research focuses on understanding how the immune system responds to Bacillus Calmette-Guérin (BCG), the only FDA-approved treatment for non-muscle-invasive bladder cancer (NMIBC). By examining the immune response, particularly the role of specific immune cells and cytokines, the study aims to identify new biomarkers and therapeutic targets that could enhance treatment effectiveness. Patients will be monitored for their immune responses to BCG, which may lead to improved treatment strategies and better management of NMIBC. The research also seeks to address the high recurrence rates of this cancer and the associated healthcare costs.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with intermediate to high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
Not a fit: Patients with muscle-invasive bladder cancer or those who have not been treated with BCG may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for non-muscle-invasive bladder cancer, potentially reducing recurrence rates and improving patient outcomes.
How similar studies have performed: Previous research has shown promise in enhancing immune responses in cancer treatment, suggesting that this approach could lead to significant advancements in bladder cancer therapy.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Horowitz, Amir — Icahn School of Medicine at Mount Sinai
- Study coordinator: Horowitz, Amir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.